Promino Nutritional Sciences Inc. announced that Dr. Patrick Gunning will assess the results of preclinical trials with various GLP-1 drugs and Promino in murine obesity models to improve muscle mass retention during weight loss. Since December 2014, when the FDA approved the first GLP-1 drug for weight loss, GLP-1 drugs have become a $35 billion industry and are forecast to exceed $100 billion by 2030. GLP-1 drug treatment is so popular that U.S. demand for the drugs, known as GLP-1 agonists, exceeded supply in 2023.

According to a May 2024 KFF Health Tracking Poll, nearly 6% of American adults say they take GLP-1 drugs for just for weight loss, with younger adults more likely than those 65 and older.  A recent UCLA Health publication states over 8.2 million prescriptions for GLP-1 were written last year in the US. A major side effect of this popular new class of weight loss drugs is rapid muscle loss.

 On GLP-1 drugs, patients can lose as much as 40% of their muscle mass.